According to Don Morel, President and Chief Executive Officer, West Pharmaceutical Services, "We are obviously stunned by the news of this incident at our Kinston facility. Our overriding concern lies with the well-being and safety of our employees, their loved ones and the surrounding community. We are in the process of gathering information and will issue a more comprehensive statement when we have the facts to share."
After speaking with West officials today, the New York Stock Exchange temporarily suspended trading of West stock. No information on the reopening of trading is currently available.
Based at West's international headquarters in Lionville, Pennsylvania, Morel and a company crisis management team are traveling immediately to the Kinston facility to guide West's continuing response to the incident.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc. (NYSE: WST) is a global drug delivery technology company that applies proprietary materials science, formulation research and manufacturing innovation to advance the quality, therapeutic value, development speed and rapid market availability of pharmaceuticals, biologics, vaccines and consumer healthcare products.
West is the world's premiere provider of standard-setting systems and device components for parenterally administered medicines and an emerging leader in the development of advanced formulation technologies for the transmucosal delivery of drugs. Internationally headquartered in Lionville, Pennsylvania, West supports its partners and customers from 50 locations throughout North America, South America, Europe, Mexico, Japan, Asia and the Pacific and Australia.
Copyright 2023 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.